Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy

Abstract excerpt

Under the selective pressure of protease inhibitor therapy, patients infected with human immunodeficiency virus (HIV) often develop drug-resistant HIV strains. One of the first drug-resistant mutations to arise in the protease, particularly in patients receiving indinavir or ritonavir treatment, is V82A, which compromises the binding of these and other inhibitors but allows the virus to remain viable. To probe...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatitis C virus research
• Share to HIV/AIDS drug development and treatment
• Share to HIV Research and Treatment